Daniel A. Scott

8.8k total citations
162 papers, 5.4k citations indexed

About

Daniel A. Scott is a scholar working on Epidemiology, Microbiology and Infectious Diseases. According to data from OpenAlex, Daniel A. Scott has authored 162 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Epidemiology, 50 papers in Microbiology and 16 papers in Infectious Diseases. Recurrent topics in Daniel A. Scott's work include Pneumonia and Respiratory Infections (121 papers), Respiratory viral infections research (95 papers) and Bacterial Infections and Vaccines (50 papers). Daniel A. Scott is often cited by papers focused on Pneumonia and Respiratory Infections (121 papers), Respiratory viral infections research (95 papers) and Bacterial Infections and Vaccines (50 papers). Daniel A. Scott collaborates with scholars based in United States, Germany and United Kingdom. Daniel A. Scott's co-authors include William C. Gruber, Emilio A. Emini, Alejandra Gurtman, Kathrin U. Jansen, Beate Schmöele-Thoma, James B. Kaper, Scott D. Patterson, Christine Juergens, Wendy Watson and Sherryl Baker and has published in prestigious journals such as New England Journal of Medicine, Blood and PLoS ONE.

In The Last Decade

Daniel A. Scott

158 papers receiving 5.3k citations

Peers

Countries citing papers authored by Daniel A. Scott

Since Specialization

Citations

This map shows the geographic impact of Daniel A. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Scott more than expected).

Fields of papers citing papers by Daniel A. Scott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Scott. The network helps show where Daniel A. Scott may publish in the future.

Co-authorship network of co-authors of Daniel A. Scott

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel A. Scott. A scholar is included among the top collaborators of Daniel A. Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel A. Scott. Daniel A. Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa 2025 ·Open Forum Infectious Diseases ·Shabir A. Madhi, Eric A. F. Simões, Nicola P. Klein, Agnieszka Zareba, Philip R. Dormitzer, Daniel A. Scott, Alejandra Gurtman, William C. Gruber, Kathrin U. Jansen, David Cooper, Bing Cai, Beate Schmöele-Thoma, Kena A. Swanson	0
2	A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan 2024 ·Vaccine ·Miwa Haranaka, Joon Young Song, Kuo‐Chin Huang, (unknown), (unknown), (unknown), (unknown), (unknown), Yahong Peng, Ingrid L. Scully, (unknown), William C. Gruber, Daniel A. Scott, Wendy Watson	6
3	Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine 2021 ·The Journal of Infectious Diseases ·James T. Peterson, Agnieszka Zareba, David Fitzpatrick, Brandon Essink, Daniel A. Scott, Kena A. Swanson, (unknown), David Radley, David Cooper, Kathrin U. Jansen, Philip R. Dormitzer, William C. Gruber, Alejandra Gurtman	31
4	A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India 2021 ·Vaccine ·Jugesh Chhatwal, (unknown), Sundaram Balasubramanian, (unknown), (unknown), (unknown), (unknown), Daniel A. Scott, Stephen Lockhart	1
5	A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age 2021 ·Human Vaccines & Immunotherapeutics ·Brandon Essink, James T. Peterson, Kari Yacisin, Himal Lal, (unknown), Xia Xu, Ingrid L. Scully, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Wendy Watson	2
6	A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6–64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines 2021 ·Vaccine ·Yoshitaka Yamazaki, Masanori Ikeda, Takayuki Imada, Kenji Furuno, Tomoyuki Mizukami, (unknown), Yasuko Shoji, (unknown), (unknown), Peter C. Giardina, Beate Schmöele-Thoma, Daniel A. Scott	2
7	A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age 2021 ·Vaccine ·Nicola P. Klein, Paula Peyrani, Kari Yacisin, (unknown), Xia Xu, Ingrid L. Scully, Daniel A. Scott, Kathrin U. Jansen, William C. Gruber, Wendy Watson	53
8	A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States 2021 ·Human Vaccines & Immunotherapeutics ·David Fitzpatrick, (unknown), Daniel A. Scott, Ingrid L. Scully, (unknown), Yahong Peng, Kathrin U. Jansen, William C. Gruber, Wendy Watson	9
9	Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence 2020 ·Human Vaccines & Immunotherapeutics ·(unknown), Daniel A. Scott, Beate Schmöele-Thoma, Wendy Watson, Mary M. Moran, Raúl Istúriz	8
10	Diabetes mellitus as a vaccine-effect modifier: a review 2020 ·Expert Review of Vaccines ·(unknown), Mark A. Fletcher, Jose A Suaya, Sally Jackson, (unknown), Daniel A. Scott, Beate Schmöele-Thoma, Raúl Istúriz, Bradford D. Gessner	20
11	Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults 2019 ·Human Vaccines & Immunotherapeutics ·Beate Schmöele-Thoma, Martin van Cleeff, Richard N. Greenberg, Alejandra Gurtman, Thomas R. Jones, Vani Sundaraiyer, William C. Gruber, Daniel A. Scott	6
12	Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial 2018 ·Human Vaccines & Immunotherapeutics ·Allison Thompson, Nicola P. Klein, H. Jackson Downey, Scott D. Patterson, Vani Sundaraiyer, Wendy Watson, (unknown), Kathrin U. Jansen, Shite Sebastian, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma	16
13	Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations 2018 ·Human Vaccines & Immunotherapeutics ·Christine Juergens, James Trammel, Yasuko Shoji, Scott D. Patterson, Wendy Watson, Chris Webber, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma	4
14	Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age 2017 ·Expert Review of Vaccines ·Raúl Istúriz, (unknown), John M. McLaughlin, Vincenza Snow, Beate Schmöele-Thoma, Chris Webber, Allison Thompson, Daniel A. Scott	12
15	Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial 2017 ·Human Vaccines & Immunotherapeutics ·(unknown), Christine Juergens, (unknown), (unknown), Vani Sundaraiyer, (unknown), Mark Cutler, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma	12
16	Pneumococcal conjugate vaccine use in adults 2015 ·Expert Review of Vaccines ·Raúl Istúriz, Beate Schmöele-Thoma, Daniel A. Scott, Luis Jódar, Chris Webber, Heather L. Sings, Peter R. Paradiso	15
17	Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico. 2013 ·PubMed ·(unknown), Allison Thompson, Douglas Girgenti, Peter C. Giardina, (unknown), William C. Gruber, Emilio A. Emini, Daniel A. Scott	4
18	BK2A78: A novel non-peptide bradykinin B2 agonist lowers intraocular pressure (IOP) in ocular hypertensive cynomolgus monkeys. 2013 ·Investigative Ophthalmology & Visual Science ·Ganesh Prasanna, Naj Sharif, (unknown), Mark R. Hellberg, (unknown), (unknown), Daniel A. Scott, Curtis R. Kelly, Iok‐Hou Pang, Keith D. Combrink	2
19	Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Vaccines in India 2012 ·The Pediatric Infectious Disease Journal ·(unknown), Sanjay Lalwani, Ashish Bavdekar, Sundaram Balasubramanian, Jugesh Chhatwal, (unknown), Valsan Philip Verghese, S. Tansey, (unknown), Qin Jiang, Michael W. Pride, Emilio A. Emini, William C. Gruber, Daniel A. Scott	16
20	Immunogenicity of booster doses of 13-valent pneumococcal conjugate and Hib/MenC vaccines given at 12 months of age in the UK 2009 ·ePrints Soton (University of Southampton) ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Eva Galiza, Daniel A. Scott, Scott D. Patterson, William C. Gruber, (unknown), Saul N. Faust, Adam Finn, Paul T. Heath, Andrew J. Pollard	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact